Our Studies
Current Studies
STEWARDS
Optimizing eScalation: CefTolozane/tazobactam vErsus treatment With trAditional anti-pseudomonal β-lactams foR pneumonia or blooDStream infections due to MDR P. aeruginosa
Prospective, Observational Study with Bacterial Isolate Collection
CONVINCE
CefiderOcol treatmeNt Versus ceftolozane/tazobactam for the treatment of pneumonia and/or bloodstream INfeCtions due to multidrug-resistant PsEudomonas aeruginosa
Retrospective Chart Review
CAMEL
Ceftazidime-Avibactam versus Meropenem-vaborbactam for the treatment of bloodstream infections and/or pneumonia due to carbapenem-resistant EnterobacteraLes
Retrospective Chart Review
TUNDRA
Management strategies for AcineTobacter baUmannii in the UNited States: Real-world evidence and clinical outcomes associated with Sulbactam-DuRlobActam
Prospective, Observational Study with Bacterial Isolate Collection
TRANSFORM
Management strategies for AcineTobacter baUmannii in the UNited States: Real-world evidence and clinical outcomes associated with Sulbactam-DuRlobActam
Prospective, Observational Study with Bacterial Isolate Collection
Upcoming Studies
Check back soon to learn more.
CACTUS
Available now in The Lancet Infectious Diseases:
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
Click here to access the final manuscript, or access our preprint here.
Publications
You can also watch and read about CACTUS in a two part series in Contagion.
CACTUS Study Compares Ceftolozane-Tazobactam vs. Ceftazidime-Avibactam for MDR Pseudomonas
>> Watch and read part 1 here
December 20, 2024
By: Sophia Abene, Jason M. Pogue
Ceftolozane Tazobactam Linked to Increased Clinical Success in Pneumonia
>> Watch and read part 2 here
December 23, 2024
By: Sophia Abene, Jason M. Pogue
MIRAGE
Effectiveness of iMIpenem-Relebactam for multidrug-resistant Pseudomonas AeruGinoa in pnEumonia and bloodstream infections in the United States
Retrospective Chart Review
Manuscript is currently in publication. Check back soon for an updated link.
Presentations
Upcoming Presentations
IMARI, Las Vegas, January 2026
Presentation - TUNDRA
Title: Preferred management strategies for Carbapenem-Resistant A. baumannii (CRAB) in the United States: Insights from the PRECEDENT Network
Please check back regularly for upcoming presentation information.
Past Presentations
IDWeek, Atlanta, October 2025
Poster Presentation - MIRAGE
Title: Effectiveness of Imipenem-Relebactam for Multidrug-resistant Pseudomonas aeruginosa in Pneumonia and Bloodstream Infections in the United States (MIRAGE)
Session: Novel Agents
IDWeek, Los Angeles, October 2024
Oral Presentations - CACTUS
Title: Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
Presented by: Dr. Jason Pogue
Title: Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
Presented by: Dr. Michael Veve
Poster Presentation - MIRAGE
Title: Effectiveness of Imipenem-Relebactam for Multidrug-resistant Pseudomonas aeruginosa in Pneumonia and Bloodstream Infections in the United States (MIRAGE)
Session: Treatment of Challenging Gram-negative Infections
34th ESCMID, Barcelona, April 2024
Oral Presentation - CACTUS
ECCMID 2024 Top Rated Abstract
Title: Time to clinical response among patients treated with ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS)
Presented by: Dr. Ryan Shields
Session: Management of infections caused by multi-drug resistant organisms: challenges and solutions
Attended ECCMID but missed the session? You can access the recording on your Online Programme.
Poster Presentation - CACTUS
Title: Efficacy of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS) among immunocompromised patients
IDWeek, Boston, October 2023
Oral Presentation - CACTUS
Title: A multicenter, observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS)
Session: Treatment of Challenging Gram-negative Infections
Attended IDWeek but missed the session? You can access the recording on idweek.org.
Want to read the abstract? Access it here.
Can’t find what you’re looking for?
Reach out here or email us directly at info@precedentnetwork.com.